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Oxidative Stress Induced by Pt(IV) 
Pro-drugs Based on the Cisplatin 
Dina Tolan , ,*, Valentina Gandin ,*, Liam Morrison El-Nahas , Cristina Marzano , 
Diego Montagner , Erxleben
The use of Pt(IV) complexes as pro-drugs that are activated by intracellular reduction is a widely 
H and 
most potent complex, cis,cis,trans-[Pt(NH ) Cl
cisplatin. Mechanistic studies revealed that the trend in cytotoxicity of the Pt(IV) complexes is primarily 
consistent with their ability to accumulate into cancer cells and to increase intracellular basal reactive 
oxygen species levels, which in turn results in the loss of mitochondrial membrane potential and 
apoptosis induction. The role of the indole acid ligand as a redox modulator is discussed.
The discovery of cisplatin and its approval by the FDA in 1978 has led to the development of the second and third 
generation platinum drugs carboplatin and oxaliplatin. Today, cisplatin, carboplatin and oxaliplatin are the most 
important anticancer drugs used in chemotherapy (Fig. 1)1–3. These three platinum(II) complexes are believed to 
operate by the same mechanism of action by undergoing hydrolysis to form the reactive aqua species which are 
responsible for the binding to purine bases in DNA to form DNA adducts and to trigger apoptosis4,5. Despite the 
clinical success of Pt(II) drugs, their usage is limited due to their drawbacks, mainly their high toxicity and severe 
side effects which arise from a lack of selectivity and their undesirable reactions with biological nucleophiles and 
proteins6,7.
One of the approaches to overcome the drawbacks of Pt(II) drugs is to use Pt(IV) complexes8–10. Octahedral 
Pt(IV) complexes can serve as pro-drugs that are activated by intracellular reduction to the corresponding Pt(II) 
agents11. Pt(IV) compounds are used to overcome the limitations of Pt(II) drugs by resisting premature aqua-
tion and unwanted binding to essential plasma proteins12. They have shown considerable promise for both oral 
administration and for reducing side effects. The most likely reason why Pt(IV) complexes such as satraplatin 
can be administrated orally–in contrast to Pt(II) drugs which are delivered intravenously–is the kinetic inert-
ness of Pt(IV) complexes due to their low spin d6 electronic configuration5. Pt(IV) complexes usually undergo 
reduction inside the cell by biological reducing agents (e.g. ascorbate, glutathione) to the active Pt(II) species 
before binding to their ultimate target DNA (Fig. 2)13. The reduction that is accompanied by the loss of the axial 
ligands has been extensively studied14. Mechanisms proposed for the reductive elimination include outer-sphere 
mechanism, inner-sphere mechanism and Pt(II)-catalyzed reaction pathways. The latter involving bridged 
Pt(II)-Pt(IV) dimers seems unlikely under cellular Pt complex concentrations. The reduction potential of cis, 
cis,trans-[Pt(amine)2X2Y2] complexes is primarily determined by the axial ligands and typically follows the order 
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Y = Cl > COOH > OH. Contrary to what would be expected, the reduction rate of Pt(IV) complexes does not 
always correlate with the reduction potential. Chlorido and hydroxido ligands can serve as electron bridges facil-
itating the faster inner-sphere electron transfer between ascorbic acid or thiol and the Pt center. By contrast, 
carboxylate ligands are poor electron transfer bridges and their complexes are generally reduced more slowly15–18. 
However, there is little clarity on the reduction rates, products and reducing agent in vivo. Recent work by Gibson 
and coworkers has suggested that the in vivo reduction of Pt(IV) complexes is chiefly mediated by biomacromol-
ecules rather than by small-molecule reducing agents such as ascorbate19. Furthermore, there is growing evidence 
that the equatorial ligands also play a role and in some cases they can be released complicating the intracellular 
fate of Pt(IV) complexes20–21.
Besides for tuning the reduction potential and thus the stability, the axial ligands of Pt(IV) pro-drugs can be 
used to modify other important pharmacological properties like lipophilicity. Furthermore, the axial coordina-
tion sites can serve as binding sites for other biologically active ligands22–26. This class of platinum complexes is 
of particular interest for the design of dual-threat pharmaceutical agents, which combine two biologically active 
components into a single molecule27–29.
Pt(IV) compounds that have recently been investigated in this context include complexes with the histone 
deacetylase inhibitors valproate and phenylbutyrate as the axial ligands as well as with dichloroacetate which is 
a known apoptosis sensitizer and anticancer agent reverting the Warburg effect30–32. Recently, Pt(IV) derivatives 
of cisplatin with the vitamin E analog α -tocopheryl succinate (α -TOS) as axial ligands were shown to exhibit a 
cytotoxic activity up to 25 times greater than that of cisplatin across several tumor cell lines, being able to induce 
nuclear DNA damage and simultaneous mitochondrial membrane depolarization33.
Here we describe the synthesis, characterization and biological properties of novel Pt(IV) complexes as cisplatin 
pro-drugs with indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) as biologically active axial ligands. 
Indole compounds are receiving considerable attention as redox modulators34–38. They have antioxidant and radical 
scavenging properties. IPA is known to protect against the oxidation of lipids39–40 and has been shown to reduce the 
autoxidation and iron-induced lipid peroxidation in hamster testes48. On the other hand, indole carboxylic acids 
can be oxidized to cytotoxic species. IAA, for example, can act as a non-toxic pro-drug that forms radicals when 
activated by redox catalysts such as horseradish peroxidase (HRP)40. This in turn can lead to enhanced cellular 
oxidative stress. Indeed, IAA is used in the oxidation therapy of cancer and for the treatment of Acne Vulgaris33,34.
The possibility of Pt(IV) complexes inducing the formation of reactive oxygen species (ROS) has been considered 
only recently41,42. Because of metabolic and signaling aberrations, cancer cells already have elevated ROS levels and 
the induction of further oxidative stress has been recognized as an attractive strategy to selectively kill cancer cells43. 
On these bases, herein we investigated the potential antitumor activity of new Pt(IV) complexes bearing IAA and 
IPA as axial ligands, focusing our attention on ROS production and mitochondrial membrane potential perturba-
tion. We hypothesized that the interplay between the redox active Pt(IV) metal center and the indole carboxylic acid 
ligands may severely unbalance cellular redox homeostasis, thus potentiating the cytotoxic effect of the Pt complexes.
Figure 1. Chemical structures of the FDA-approved Pt(II) drugs and the Pt(IV) pro-drug in clinical trials, 
satraplatin. 
Figure 2. Activation by reduction of Pt(IV) complexes. 
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Synthesis and Characterization. Ten indole carboxylic acid Pt(IV) complexes with IAA (indole-3-acetic 
acid, 1A–5A) and IPA (indole-3-propionic acid, 1P–5P) were synthesized and the structures are depicted in Fig. 3. 
The monocarboxylato complexes 1A and 1P were prepared by reacting oxoplatin, c,c,t-[Pt(NH3)2Cl2(OH)2], 
with 0.8 eq. of the activated NHS-ester of the corresponding indole carboxylic acid. The dicarboxylato complexes 
with two indole acids in axial position (2A and 2P) were obtained using an excess of the NHS-ester activated acid 
(20 eq.), since the second hydroxo group of oxoplatin is much less reactive than the first one. The unsymmetrically 
substituted complexes (3A–5A and 3P–5P) were prepared by reaction of the monocarboxylate complexes 1A and 
1P with the corresponding anhydrides. We chose three different anhydrides (benzoic, acetic and succinic anhy-
dride) to vary the lipophilicity of the resulting Pt(IV) complexes. All the synthesized Pt(IV) complexes were char-
acterized using elemental analysis, ESI-MS, FT-IR, 1H and 195Pt NMR spectroscopy. The purity of the complexes 
has been assessed through elemental analysis and–where solubility was not an issue–by high performance liquid 
chromatography (HPLC). The dicarboxylato complexes are poorly soluble in organic solvents. The proton NMR 
spectra of the complexes in DMSO-d6 show the typical signal of the NH3 protons which is a multiplet at around 
6 ppm for the monocarboxylato complexes 1P and 1A (typical 1JNH and 2JPtH values around 50 Hz) while it is a 
broad signal around 6.5 ppm for the bis-substituted complexes (2–5A and 2–5P, Supplementary Information)44. 
The mass spectra of the complexes show a peak in the negative mode with the typical platinum isotope pattern 
corresponding to M − H− or M + Cl−. Stability studies on representative examples of the complexes (1A, 1P, 3A 
and 3P) via mass spectrometry confirm that the complexes are stable in physiological saline (0.9% NaCl) for at 
least 48 h (Supplementary Information).
The reduction reaction of two representative complexes (1A and 1P) and the release of the indole carboxylic 
acid ligands was analyzed by HPLC using ascorbic acid as the reductant and 37 °C, pH 7 as physiological con-
ditions (Fig. 4 and S1). The HPLC chromatograms of the reduction reaction of the complexes were compared 
with the chromatograms of pure samples of the carboxylic acid ligands. The results indicated that the complexes 
release the indole carboxylic acid ligands upon reduction from Pt(IV) to Pt(II). After 3 h incubation with 10 eq. of 
ascorbic acid 75% of 1P and 50% of 1A was reduced. Complex 1P was completely reduced after 24 h, while com-
plex 1A was completely reduced after 30 h. We further studied the nature of the Pt(II) species produced upon the 
reduction of 1P and 1A by 195Pt NMR. Figure 5 and S2 show that the reaction of 1P and 1A with 1 eq. of ascorbic 
acid resulted in a strong signal for cisplatin at − 2096 ppm45,46. The complexes were completely reduced after 24 h 
(1P) and 30 h (1A) of incubation with ascorbic acid at 37 °C, in line with the HPLC analyses. Unfortunately, 
monitoring the reduction reaction of the symetrically (2A and 2P) and unsymmetrically (3A–5A and 3P–5P) 
substituted dicarboxylato complexes was hampered by the poor solubility of the complexes in water and most 
organic solvents except DMF and DMSO. For the same reason the reduction potentials could not be determined 
by cyclic voltammetry. However it has been reported that the reduction rate of cis,cis,trans-[Pt(NH3)2Cl2(RCOO)
(OH)] monocarboxylato complexes is faster than that of dicarboxylato complexes and this has been attributed to 
the fact that hydroxido ligands are much better bridging ligands for electron transfer than carboxylate ligands45.
It is known that the activity of cisplatin is mainly due to DNA damage caused by its ability to bind to the N7 
position of guanine bases. To mimic the intracellular reduction, complex 1P was reduced with sodium ascorbate 
in the presence of guanosine to simulate the interaction of the platinum drug with DNA in vitro. The reduction of 
1P followed by the reaction with guanosine (G) led to the formation of the PtII/GG bisadduct [Pt(NH3)2(G-N7)2] 
(m/z 795 in the mass spectrum, Figure S3, Supplementary Information). This suggests that cisplatin formed upon 
reduction of 1P will interact efficiently with nuclear DNA.
Cytotoxicity. The cytotoxic activity of the complexes and of the uncoordinated ligands was evaluated by the 
MTT test on a panel of human tumor cell lines containing examples of pancreatic (BxPC3), colorectal (HCT-15), 
breast (MCF-7), cervical (A431), and lung (A549) cancers as well as of melanoma (A375). For comparison 
Figure 3. Structures of the ten Pt(IV) complexes described in this paper. 
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purposes, the cytotoxicity of cisplatin was evaluated under the same experimental conditions. IC50 values, cal-
culated from the dose-survival curves obtained after 72 h of drug treatment, are shown in Table 1. The uncoor-
dinated ligands proved to be hardly effective against all tested cancer cell lines, whereas the newly synthesized 
Pt(IV) complexes were able to promote a significant cancer cell killing effect. Noteworthy, they were extremely 
effective against human lung A549 cancer cells, notoriously poor sensitive to platinum drugs, being on average 
2.4-fold more cytotoxic than cisplatin. Among all complexes, the monohydroxido complex with indole propionic 
acid, 1P, showed the highest cytotoxic activity, with a mean IC50 value of about 2.5 μ M, roughly three times lower 
than that calculated for cisplatin (mean IC50 = 8.33 μ M). Similarly, the unsymmetrically dicarboxylated complex 
3P with benzoic acid exhibited a cytotoxicity profile comparable to that of the derivative 1P, with an average IC50 
value of 2.6 μ M. By contrast, compounds 4A, 4P and 5A appear to be the least cytotoxic in all the considered cell 
lines, with mean IC50 values up to one order of magnitude higher than those calculated for 1P and up to nine 
times higher than those calculated for cisplatin. In general, regarding the indole propionic acid series, the mono-
carboxylated Pt(IV) complex 1P was more effective than the dicarboxylato Pt(IV) derivative. Indeed, the intro-
duction of a second carboxyl ligand to the other axial position, forming the symmetrically disubstituted derivative 
2P, led to a 50% decrease of cytotoxic activity (mean IC50 equal to 2.5 and 4.9 μ M for 1P and 2P, respectively). 
The introduction of a second and different carboxyl ligand (benzoate, acetate or succinate) in axial position led 
to Pt(IV) derivatives for which the activity profile depends on the nature of the substituent. More precisely, the 
complex bearing the most lipophilic benzoate ligand, 3P, showed the highest in vitro antiproliferative activity 
(mean IC50 equal to 2.6 μ M), whereas the complexes with a more hydrophilic carboxylate, such as succinate and 
acetate, 4P and 5P, were endowed with a lower cytotoxic activity (mean IC50 of 30.4 and 11.1 μ M, respectively). A 
rather similar behavior occurred with the Pt(IV) complexes with indole acetic acid in axial positions. Again 1A, 
which presents a single axial carboxylate ligand, appeared to be the most active compound, with mean IC50 values 
about 2.5 times lower than those obtained with the reference chemotherapeutic metallo-drug. Coherently, when 
Figure 4. HPLC chromatogram of the reaction of 1P with 10 eq. ascorbic acid (AsA) at 37 °C and pH 7. The 
chromatogram of the free ligand (IPA) is shown for comparison purposes.
Figure 5. 195Pt NMR spectra of (a) complex 1P and (b) after reacting 1P with ascorbic acid for 24 h at 37 °C. 
Zooms of the 600 to 1400 and − 2300 to − 2000 ppm regions are shown.
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a second and different axial carboxylate ligand was introduced, the activity correlated with the lipophilicity of this 
ligand, i.e. 3A > 5A > 4A.
It is important to notice that the most cytotoxic derivatives 1A and 1P were about two times (in HCT-15 cells) 
and four times (in BxPC3 and A549 cells) more effective than cisplatin in inhibiting cancer cell proliferation.
Cross-resistance studies. The cytotoxic properties of the complexes were also evaluated in a pair of tumor 
cell lines suitably selected for their sensitivity and resistance to cisplatin (adenocarcinoma cells 2008/C13*). 
Cross-resistance profiles were evaluated by means of the resistance factor (RF), defined as the ratio between IC50 
values calculated for the resistant cells and those obtained with the sensitive ones (Table 2). The phenomenon of 
cisplatin resistance is multifactorial in nature. Nevertheless, the main molecular mechanisms involved in drug 
resistance in C13* cancer cells have largely been identified. Indeed, in this cell line resistance is correlated to high 
cellular glutathione and thioredoxin reductase levels47, reduced cellular drug uptake and enhanced repair of DNA 
damage48. All derivatives demonstrated a similar cytotoxic profile, both in cisplatin-sensitive and -resistant cell 
lines, with a cytotoxicity pattern highly similar to that described above, with complexes 1A and 1P again being the 
most active complexes in the two series. The RF values calculated for all derivatives were six- to nine-fold lower 
than that of cisplatin, clearly indicating the absence of cross-resistance.
One of the key factors determining the biological activity of a 
metal-based compound is its ability to cross cell membranes and to accumulate into cancer cells. Therefore, in 
order to correlate the antiproliferative effect shown by the complexes and their cellular accumulation, the plati-
num content was evaluated in A375 cells following treatment with equal doses (1.5 and 3 μ M) of the tested com-
pounds for 6 and 24 hours. The intracellular metal amount was quantified by means of graphite furnace atomic 
Complex
IC50(μM) ± S.D.
BxPC3 HCT-15 MCF-7 A431 A549 A375
1P 2.26 ± 0.99 3.66 ± 0.91 3.78 ± 0.16 1.62 ± 0.34 2.66 ± 0.54 0.76 ± 0.02
1A 2.64 ± 0.97 9.00 ± 3.13 3.62 ± 0.94 2.10 ± 1.04 3.62 ± 0.23 1.31 ± 0.82
2P 2.56 ± 0.65 14.00 ± 1.56 5.54 ± 0.67 3.00 ± 0.35 2.87 ± 1.59 1.35 ± 0.75
2A 3.32 ± 0.21 25.18 ± 0.89 3.70 ± 0.29 13.32 ± 0.84 3.75 ± 1.31 1.85 ± 0.23
3P 2.92 ± 1.13 5.94 ± 0.63 2.28 ± 0.46 2.00 ± 0.32 0.96 ± 0.06 1.51 ±  1.25
3A 2.56 ± 1.07 3.67 ± 1.31 3.76 ± 0.76 6.31 ± 0.94 2.59 ± 0.13 3.53 ± 0.60
4P > 50 41.99 ± 1.92 40.56 ± 0.08 29.25 ± 4.19 11.75 ± 1.06 8.66 ± 4.03
5P 19.50 ± 0.68 14.03 ± 0.14 21.01 ± 0.06 5.35 ± 2.11 3.62 ± 0.18 3.15 ± 0.02
4A > 50 > 50 > 50 3.94 ± 0.57 18.11 ± 4.32 48.52 ± 1.48
5A 44.44 ± 6.19 44.75 ± 0.07 43.26 ± 0.22 3.07 ± 0.31 2.80 ± 0.09 26.92 ± 4.04
IAA > 50 > 50 > 50 > 50 > 50 > 50
IPA > 50 > 50 > 50 > 50 > 50 > 50
cisplatin 10.17 ± 1.65 15.53 ± 2.48 7.60 ± 2.96 1.96 ± 0.84 12.64 ± 0.81 2.06 ± 1.01
Table 1.  IC50 values of the complexes in different cancer cell lines. Cells (3– 8 × 103 m−1) were treated for 72 h 
with increasing concentrations of tested compounds. Cytotoxicity was assessed by MTT test. IC50 values were 
calculated by four parameter logistic model (p < 0.05). S.D. = standard deviation.
IC50(μM) ± D.S.
Complex 2008 C13* RF
1P 1.45 ± 0.37 1.14 ± 0.50 0.8
1A 2.89 ± 1.22 2.51 ± 1.50 0.9
2P 8.37 ± 2.12 2.91 ± 0.64 0.4
2A 11.01 ± 2.14 3.44 ± 0.59 0.3
 3A 9.97 ± 3.18 6.52 ± 1.96 0.7
3P 4.79 ± 0.69 1.47 ± 0.68 0.3
4P > 50 > 50 − 
5P 18.04 ± 1.33 21.85 ± 2.48 1.2
4A > 50 > 50 − 
5A 41.21 ± 0.75 46.58 ± 3.41 1.1
cisplatin 2.26 ± 1.06 23.73 ±  ± 2.42 10.5
Table 2.  IC50 values of the compounds in cisplatin-sensitive and cisplatin-resistant cell lines. Cells 
(3–8 × 103 m−1) were treated for 72 h with increasing concentrations of tested compounds. Cytotoxicity was 
assessed by MTT test. IC50 values were calculated by four parameter logistic model (p < 0.05). S.D. = standard 
deviation. Resistant Factor (RF) is defined as IC50 resistant/parent line.
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absorption spectroscopy (GF-AAS), and the results, expressed as pg of metal per 106 cells, are shown in Fig. 6, 
panel A and B. Although to a different extent, all complexes accumulated proportionally to their concentration 
and in a time-dependent manner. Among all derivatives, 1P and 3P were internalized most efficiently. In particu-
lar, following 24 h exposure, the amount of platinum detected in cells treated with 1P at 3 μ M concentration was 
about 2.3 times greater than that observed in cells treated with the same dose of cisplatin. By contrast, 4A and 4P 
gave the lowest platinum accumulation in treated cells, with cellular uptake levels about 7 times lower compared 
to cisplatin.
It is well known that the main cellular target of platinum complexes is the DNA, and platination of nuclear 
DNA is a critical step in triggering the death of cancer cells by platinum-based drugs. On this basis, the amount 
of platinum bound to nuclear DNA was also assessed in A375 cells treated with the tested Pt(IV) complexes. 
Cells were treated for 24 h with 5 μ M of the tested complexes, the nuclear DNA was isolated and the amount 
of Pt in each sample was determined by means of GF-AAS analysis. The results expressed as pg Pt/ng DNA are 
depicted in Fig. 7. Notably, all Pt(IV) complexes elicited a degree of DNA platination significantly higher than 
that of cisplatin. Among all tested compounds, the least effective ones in interacting with cellular DNA were the 
IPA derivatives 4P and 5P, whereas compound 1P led to the highest degree of DNA platination. In particular, 1P 
led to a roughly 60-fold higher DNA platination level with respect to cisplatin. Considering the IAA series, the 
derivatives 1A and 3A led to the most effective platination of cellular DNA, whereas 4A and 5A were endowed 
with the lowest DNA platination capability.
Partition coefficients (logP values) for octanol/water partition were determined in order to examine whether 
a correlation exists between lipophilicity and accumulation into cells. The log P values obtained (Table 3) give 
the trend in lipophilicity as mono indole acid complex < succinate complex < acetate complex < bis indole acid 
complex < benzoate complex for both the IAA and the IPA series.
ROS are products of normal cell metabolism but their levels can be increased upon expo-
sure to toxic agents or interference with the cellular redox network. Notably, as described in the introduction, 
indoles in the presence of HRP or other redox catalysts, can be transformed intracellularly into pro-oxidants, able 
to unbalance the cellular redox state and provoking an increase in oxidative stress40. Consequently, cellular ROS 
Figure 6. Cellular uptake of Pt(IV) complexes in A375 melanoma cells. (A) A375 cells incubated for 6 and 
24 h with the complexes at 3 μ M concentration. (B) A375 cells incubated for 24 h with the complexes at 1.5 and 
3 μ M concentration. The intracellular platinum content was determined by GF-AAS.
Figure 7. Nuclear DNA platination levels in A375 cells treated for 24 h with 5 μM of the tested complexes. 
The amount of Pt in each sample was determined by means of GF-AAS analysis.
www.nature.com/scientificreports/
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levels upon treatment with equal doses (12.5 μ M) of the different platinum complexes were monitored in A375 
cancer cells by using the peroxide-sensitive fluorescent probe CM-H2DCFDA (5-(and-6)-chloromethyl-2′ ,7′ - 
dichlorodihydrofluorescein diacetate, acetyl ester). Antimycin, a classical inhibitor of the mitochondrial respira-
tory chain at the level of complex III, was used as a positive control. The results, expressed as arbitrary units of 
fluorescence as a function of time, are shown in Fig. 8.
Interestingly, all IPA complexes were able to substantially stimulate the production of hydrogen peroxide in a 
time-dependent manner (Fig. 8, panel A), while the free IPA and IAA ligands in the absence of Pt had no effect 
on cellular basal ROS levels. In particular, 1P induced an increase in ROS production that was superior to that 
induced by antimycin, whereas 2P enhanced ROS production to a similar extent as the respiratory chain complex 
III inhibitor. Also the IAA complexes 1A and 3A were able to increase the H2O2 production to a similar extent as 
antimycin, whereas 2A was less effective compared to the positive control (Fig. 8, panel B). Conversely, treatment 
of A375 cells with 4A and 5A did not alter the cellular ROS concentration.
Mitochondrial membrane potential. A persistent increase in the rate of ROS production is responsible 
for the accumulation of ROS. In turn, an increase in cellular ROS leads to the loss of the mitochondrial mem-
brane potential (Δ Ψ m, MMP), thus possibly leading to the induction of apoptosis. The effect induced by the 
Pt(IV) complexes on the MMP was assessed by treating A375 cells with IC50 concentrations of 1P and 1A and 
evaluating the energization of treated melanoma cells in terms of the retention of the cationic fluorescent probe 
tetramethyl rhodamine methyl ester (TMRM). Compared to control cells, both derivatives elicited a significant 
and time-dependent increase in the percentage of cells with a decreased MMP (Fig. 9).
Complex Log P Complex Log P
1P − 0.110 ± 0.05 1A − 0.220 ± 0.04
2P − 0.051 ± 0.06 2A − 0.068 ± 0.07
3P − 0.028 ± 0.07 3A − 0.037 ± 0.04
4P − 0.100 ± 0.05 4A − 0.190 ± 0.06
5P − 0.080 ± 0.04 5A − 0.130 ± 0.05
Table 3.  Log P (octanol/water) values of the Pt(IV) complexes.
Figure 8. ROS production in A375 cells. Cells were preincubated in PBS/10 mM glucose medium for 20 min 
at 37 °C in the presence of 10 μ M CM-DCFDA and then treated with equimolar doses (12.5 μ M) of indole 
propionic acid Pt(IV) derivatives (panel A) or indole acetic acid Pt(IV) derivatives (panel B). The fluorescence 
of DCF was measured.
www.nature.com/scientificreports/
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Mechanism of cell death. In order to characterize cell death pathways activated in response to treatment 
with the most effective compounds 1P and 1A, we examined their effects in terms of apoptosis induction in 
A375 cells. Figure 10A shows the results obtained upon monitoring cellular morphological changes in A375 cells 
treated for 48 h with IC50 doses of 1P and 1A using Hoechst 33258 fluorescent staining analysis. Compared with 
control cells, treated cells presented brightly stained nuclei and morphological features typical of cells undergoing 
apoptosis, such as chromatin condensation and fragmentation.
Testing the ability of 1P and 1A to activate caspase-3, a well-known executor enzyme in the apoptotic pathway, 
it was found that both complexes markedly stimulated caspase-3 activity (Fig. 10B).
In particular, following a 48 h treatment with IC50 doses of 1P and 1A, the protease activity was enhanced 
roughly by a factor of 5 over untreated control cells. Caspase-3 cleavage reached values similar to that exerted by 
the well-known caspase-dependent apoptosis inducer staurosporine. Interestingly, pre-treatment of cancer cells 
with zVAD, a cell-permeable pan-caspase inhibitor, strongly decreased caspase activation induced by the Pt(IV) 
complexes, thus confirming the role played by these proteases in cell death caused by these derivatives.
Figure 9. Effects of 1P and 1A on the cellular mitochondrial membrane potential. A375 cells were treated 
for 24 and 48 h with IC50 concentrations of 1P or 1A and stained with TMRM (10 nM). The percentage of cells 
with a hypopolarized mitochondrial membrane potential was determined fluorimetrically.
Figure 10. (A) Hoechst staining of A375 cells incubated for 48 h with IC50 doses of 1P (b) and 1A (c). Panel a 
represents untreated A375 cells as control. (B) Caspase-3 activity upon incubation of A375 cells for 48 h with 
IC50 doses of 1P and 1A.
www.nature.com/scientificreports/
9SCIENTIFIC REPORTS
Discussion
Ten indole carboxylic acid Pt(IV) derivatives have been successfully synthesized and characterized. Among all the 
complexes, promising in vitro antitumor activity was found for Pt(IV) complexes based on the cisplatin scaffold, 
bearing one axial indole carboxylate and one axial hydroxido ligand (1A and 1P). The cytotoxicity studies carried 
out on a large panel of human tumor cell lines have revealed that, generally, complexes with IPA (indole propionic 
acid) ligands were on average more cytotoxic than complexes with IAA (indole acetic acid) ligands. In particular, 
the monocarboxylated complex 1P showed an antiproliferative activity approximately three times superior to that 
of cisplatin. In addition, all the complexes are able to overcome cisplatin-resistance. Platinum uptake experiments 
showed that all the Pt(IV) complexes are internalized inside cancer cells better than cisplatin, with 1P being the 
ablest to accumulate into cells. Thus, noteworthy, the trend in cellular accumulation cannot be directly related to 
the lipophilicities of the complexes. Indeed, the most efficient internalization is observed for the least lipophilic 
complex 1P. Although a higher lipophilicity should lead to an enhanced cellular uptake, as Pt(IV) complexes 
(unlike Pt(II) complexes) enter cells solely by passive diffusion, a lack of correlation between logP values and 
cellular Pt levels is not unprecedented31,32.
By correlating the data of cellular uptake with those arising from the cytotoxicity studies following 24 h of 
treatment, a direct correlation between cytotoxic activity and cellular uptake is revealed, albeit to a different 
extent for the IPA (Fig. 11, panel A) and IAA series (Fig. 11, panel B). Actually, the inverse correlation between 
IC50 values and cellular platinum content was much more pronounced in A375 cells treated with indole propi-
onic acid derivatives (R2 = 0.71) compared to results obtained with the indole acetic acid complexes (R2 = 0.42). 
However, by comparing the cytotoxicity results with DNA platination levels elicited by the Pt(IV) complexes, 
no linear correlation was found. Taken together, these data strongly support the hypothesis that different targets 
could account for the antiproliferative effects of these newly synthesized Pt(IV) compounds.
The higher potency of 1P compared to the other derivatives thus appeared to be primarily due to its greater 
accumulation into cells and its ability to induce ROS formation. Actually, the most interesting result of the pres-
ent study is the fact that some of the complexes were very efficient ROS producers. In particular, 1P induced a 
dramatic increase in cellular ROS basal production, thus leading to a massive mitochondrial membrane potential 
loss. From a mechanistic point of view, we can speculate that, upon reduction of Pt(IV) to Pt(II), the released 
indole carboxylic acid undergoes oxidation and turns into a pro-oxidant species. In such a scenario, redox cycles 
could be triggered at the intracellular level that shift the redox state towards a more oxidized state (Fig. 12). In this 
context it is noteworthy that IAA and IPA alone did not elicit any significant cytotoxic effect.
Therefore, the introduction of redox modulators in the axial positions in a Pt(IV) complex can potentiate 
the antiproliferative effects through simultaneous DNA platination and ROS generation, both known triggers 
of apoptosis. The most potent complex, 1P, is the most efficient ROS producer and gives the highest degree of 
DNA platination. Indeed, P1 shows the highest level of loss of mitochondrial membrane potential and strongly 
enhances the caspase 3 activity (Fig. 9). Overall, the results of this study support the hypothesis that the Pt(IV) 
indole acid complexes have multifactorial targets.
Conclusions
In summary, coordinating redox modulators to the axial positions of Pt(IV) complexes appears to be a profitable 
strategy for obtaining new promising anticancer agents. In particular, our work pointed out that the presence of 
indole acids in axial position of Pt(IV) prodrugs increases the production of ROS in the cellular environment, 
thus determining the loss of the mitochondrial membrane potential, ultimately leading to cancer cell death. This 
dual-threat mechanism combining the effects of DNA platination and ROS generation drives cancer cells to a 
caspase-dependent apoptotic cell death. In conclusion, the present study highlights the potential for developing 
Pt(IV) complexes with redox modulators as antitumor pro-drugs.
Figure 11. Correlation between cytotoxicity (IC50) and cellular platinum levels in drug-treated A375 cells. 
(A) propionic acid derivatives 1P–5P, (B) acetic acid derivatives 1A–5A.
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Methods
Materials and Syntheses. All reactions were carried out under normal atmospheric conditions. Solvents 
and chemicals were of analytical grade or HPLC grade and were obtained from commercial sources. The ultrapure 
water used was purified by a Milli-Q UV purification system. K2PtCl4 was obtained from Acros Organics. Indole-
3-acetic acid, indole-3-propionic acid, succinic anhydride and acetic anhydride were obtained from Sigma-
Aldrich. Benzoic anhydride, N-hydroxysuccinimide and dicyclohexylcarbodiimide were purchased from TCI. 
All chemicals were used as received. Cisplatin and oxoplatin were synthesized as previously reported49,50.
In general, the monocarboxylato complexes 1A and 1P were obtained by reaction of oxoplatin with 0.8 eq. 
of the corresponding activated NHS-ester of indole-3-acetic or indole-3-propionic acid in DMSO at 50 °C. The 
bis-indole acid complexes (2A and 2P) were obtained in the same way using a ten-fold excess of the activated 
ligand in DMSO at 60 °C. The unsymmetrically biscarboxylated complexes were obtained by reaction of the cor-
responding monohydroxido species 1A or 1P with benzoic anhydride (3A and 3P), succinic anhydride (4A and 
4P) or acetic anhydride (5A and 5P). Details on the syntheses and 1H, 13C, 195Pt NMR and mass spectra for all the 
complexes are reported in the Supplementary Information.
Measurements. 1H NMR and 13C NMR spectra were recorded on a Jeol ECX-400. Chemical shifts (δ ) 
are reported in parts per million (ppm) and referenced internally using the residual solvent signals relative to 
tetramethylsilane (δ (1H NMR) = 0 ppm). Coupling constants J are reported in Hertz. One dimensional 195Pt 
NMR spectra were recorded on a Varian 500 AR spectrometer in DMF with insert D2O. K2PtCl6 in D2O was 
used as an external standard. Mass spectra were measured using a Waters LCT Premiere XE with electron spray 
ionisation and time of flight mass analyser. Elemental analysis (carbon, nitrogen and hydrogen) were performed 
by an Exeter Analytical CE-440. FT-IR spectra were recorded on a PerkinElmer FT-IR spectrometer fitted with an 
ATR accessory. A dynamic reaction cell ICP-MS (ELAN DRCe, Perkin Elmer, Waltham, USA), equipped with a 
flow injection autosampler (FIAS 93 plus) was employed for platinum determination51–54. Instrumental operating 
conditions were the following: ICP RF Power 1150 W: plasma gas flow 15 L min−1, auxiliary gas flow 1 L min−1, 
nebuliser gas flow 0.93 L min−1, observed isotopes, 192Pt, 194Pt, 195Pt, 196Pt and 198Pt) . Calibration standard solu-
tions were prepared from a single element standard (Inorganic Ventures, 1000 μ g mL−1) prepared in Milli-Q™ 
water (18.3 mΩ) (Millipore, Bedford, USA) with 1% HNO3 (Trace Metal Grade, 67–69%, Fisher, UK). Iridium 
(191Ir) and indium (115In) were used as internal standards to account for instrumental drift and matrix effects. The 
HPLC studies were carried out using an Agilent 1200 series DAD analytical HPLC instrument.
The reduction of the complexes 1A and 1P) with ascorbic acid 
was followed by HPLC using a Phenomenex Luna C18 (5 μ M, 100 Å, 250 mm × 4.60 mm i.d.) column at a flow 
rate of 1.0 mL/min with 280 nm UV detection at room temperature. The mobile phase was 80:20 acetonitrile (1% 
trifluoroacetic acid) : water (1% trifluoroacetic acid). The complexes were dissolved in DMF (0.5 mL) and added 
to a 5 mM solution of ascorbic acid in 2 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) buffer 
(pH 7) and diluted to a final concentration of 0.5 mM using acetonitrile. The process was followed at 37 °C until 
complete reduction.
Compounds 1A and 1P (10 mM) were incu-
bated at 37 °C, respectively, in the presence of 10 mM ascorbic acid in 12 mM HEPES buffer at pH 7. The com-
pounds were dissolved in DMF and then ascorbic acid and aqueous buffer solution was added (the concentrations 
given are the final concentrations). The reaction was followed until complete reduction of the complexes. The 
195Pt NMR spectra were recorded by inserting a tube with D2O into the NMR tube.
Complex 1P (1.5 mg, 3 μ mol) and guanosine (4.24 mg, 
15 μ mol) was dissolved in 1 mL DMF and a 15 mM aqueous solution of sodium ascorbate (1 mL) was added. The 
mixture was kept at 37 °C for 24 h. Thereafter, the mixed solution was analyzed by ESI-MS.
Determination of lipophilicity parameters. The logP values of the Pt(IV) compounds were determined 
using the shake flask method55. The respective Pt(IV) complex was dissolved in 0.9% NaCl (w/v) ultrapure water 
(presaturated with n-octanol). The solutions were sonicated and filtered to remove undissolved Pt(IV) com-
pounds. The initial Pt concentrations were determined by ICP-MS. Subsequently, the Pt(IV) solutions were added 
to an equal volume of n-octanol (presaturated with 0.9% NaCl (w/v) ultrapure water). The heterogeneous mix-
tures were shaken vigorously for 30 min before centrifuging at 4000 rpm for 30 min to achieve phase separation. 
Figure 12. Proposed mechanism of ROS formation by Pt(IV) complexes with indole carboxylic acid 
ligands. 
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The final Pt concentration in the aqueous phase was determined again by ICP-MS. The logarithm of the ratio of Pt 
concentrations in the organic and aqueous phases was calculated to determine the logP values. All experiments 
were done in duplicate.
Stability studies. Complexes 1A, 1P, 3A and 3P where dissolved in a minimum amount of DMF and diluted 
1:20 with physiological saline (0.9% NaCl). Mass spectra were recorded at t = 0 and after 48 hours.
Experiments with cultured human cells. The Pt(IV) compounds were dissolved in DMSO just before 
running the experiment and a calculated amount of drug solution was added to the cell growth medium to a final 
DMSO concentration of 0.5%, which had no detectable effect on cell viability. Cisplatin was dissolved in 0.9% 
NaCl solution.
Cell cultures. Human breast (MCF-7), colon (HCT-15), lung (A549) and pancreatic (BxPC3) carcinoma 
cell lines together with melanoma (A375) cells were obtained from American Type Culture Collection (ATCC, 
Rockville, MD). The human ovarian cancer cell line 2008 and its cisplatin resistant variant, C13* , were kindly 
provided by Prof. G. Marverti (Department of Biomedical Science of Modena University, Italy). Human cervical 
carcinoma (A431) cells were kindly provided by Prof. F. Zunino (Division of Experimental Oncology B, Istituto 
Nazionale dei Tumori, Milan, Italy). Cell lines were maintained in the logarithmic phase at 37 °C in a 5% carbon 
dioxide atmosphere using the following culture media containing 10% fetal calf serum (Euroclone, Milan, Italy), 
antibiotics (50 units/mL penicillin and 50 μ g/mL streptomycin) and 2 mM L-glutamine: (i) RPMI-1640 medium 
(Euroclone) for 2008, C13* , MCF-7, HCT-15, A431 and BxPC3 cells, (ii) F-12 HAM’S (Sigma Chemical Co.) for 
A549 cells, iii) DMEM (Sigma Chemical Co.) for A375 cells.
Cytotoxicity assays. The growth inhibitory effect toward tumor cells was evaluated by means of the MTT 
assay. Briefly, (3–8) × 103 cells/well, dependent upon the growth characteristics of the cell line, were seeded in 
96-well microplates in growth medium (100 μ L). After 24 h, the medium was removed and replaced with fresh 
medium containing the compound to be studied at the appropriate concentration. Triplicate cultures were estab-
lished for each treatment. After 24, 48, or 72 h, each well was treated with 10 μ L of a 5 mg/mL MTT saline solution 
and, after 5 h of incubation, 100 μ L of a sodium dodecylsulfate (SDS) solution in 0.01 M HCl was added. After an 
overnight incubation, cell growth inhibition was detected by measuring the absorbance of each well at 570 nm 
using a Bio-Rad 680 microplate reader. The mean absorbance for each drug dose was expressed as a percentage 
of the control, untreated well absorbance and plotted vs drug concentration. The IC50 values, the drug concentra-
tions that decrease the mean absorbance at 570 nm to 50% of that of untreated control wells, were calculated from 
the dose–response curves with the four-parameter logistic model (4PL). The final value is the mean ± S.D. of at 
least three independent experiments performed in triplicate.
Cellular accumulation of Pt. A375 cells (2 × 106) were seeded in 75 cm2 flasks in growth medium (20 mL). 
After 24 h, the medium was replaced and the cells incubated for 6 or 24 h with the tested complexes. Cell mon-
olayers were washed twice with cold phosphate-buffered saline (PBS), harvested and counted. Samples were 
subjected to three freeze-thaw cycles at − 80 °C, and then vigorously vortexed. The samples were treated with 
highly pure nitric acid (1 mL, Pt ≤ 0.01 mg·kg−1, Trace-SELECT Ultra, Sigma Chemical Co.) and transferred into 
a microwave teflon vessel. Subsequently, samples were submitted to standard mineralization procedures. Samples 
were analyzed for platinum by using a Varian AA Duo graphite furnace atomic absorption spectrometer (Varian, 
Palo Alto, CA, USA) at a wavelength of 324.7 nm. The calibration curve was obtained using known concentrations 
of standard solutions purchased from Sigma Chemical Co.
A375 cells (3 × 106) were seeded in 10 cm Petri dishes in 10 mL of culture medium. 
Subsequently, cells were treated with the tested complexes (5 μ M) for 24 h. The DNA was extracted and purified 
by a commercial spin column quantification kit (Qiagen DNeasy Blood and Tissue Kit). Only highly purified 
samples (A260/A230 ≅ 1.8 and A280/A260 ≅ 2.0) were included for analysis to avoid any artifacts. The samples 
were completely dried and re-dissolved in 200 μ L of Milli-Q water (18.2 MΩ) for at least 20 min at 65 °C in a shak-
ing thermo-mixer, mineralized and analyzed for total Pt content by GF-AAS as described above.
The production of ROS was measured in A375 cells (104 per well) grown for 24 h in 96-well 
plates in DMEM medium without phenol red (Sigma Chemical Co.). Cells were then washed with PBS and loaded 
with 10 μ M 5-(and-6)-chloromethyl-2′ ,7′ -dichlorodihydrofluorescein diacetate, acetyl ester (CM–H2DCFDA) 
(Molecular Probes-Invitrogen) for 25 min in the dark. Afterwards, cells were washed with PBS and incubated with 
increasing concentrations of the tested complexes. The fluorescence increase was estimated with a plate reader 
(Fluoroskan Ascent FL, Labsystem, Finland) at 485 (excitation) and 527 nm (emission). Antimycin (3 μ M, Sigma 
Chemical Co.), a potent inhibitor of Complex III in the electron transport chain, was used as positive control.
Mitochondrial membrane potential (ΔΨm). The Δ Ψ m was assayed using the Mito-ID® Membrane 
Potential Kit according to the manufacturer’s instructions (Enzo Life Sciences, Farmingdale, NY). Briefly, A375 
cells (8 × 103 per well) were seeded in 96-well plates, after 24 h, cells were washed with PBS and loaded with 
Mito-ID Detection Reagent for 30 min at 37 °C in the dark. Afterwards, cells were washed with PBS and incu-
bated with increasing concentrations of the tested complexes. The fluorescence was estimated using a plate reader 
(Fluoroskan Ascent FL, Labsystem, Finland) at 490 (excitation) and 590 nm (emission).
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A375 cells were seeded into 8-well tissue-culture slides (BD Falcon, Bedford, MA, 
USA) at 5 × 104 cells/well (0.8 cm2). After 24 h, cells were washed twice with PBS and following 48 and 72 h of 
treatment with IC50 doses of the tested compound, cells were stained for 5 min with 10 μ g/mL of Hoechst 33258 
(2′ -(4-hydroxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5′ -bi-1H-benzimidazole trihydrochloride hydrate, Sigma–
Aldrich) in PBS before being examined by fluorescence microscopy (Olympus).
A375 cells (1 × 106) were treated for 24 h with the IC50 doses of tested com-
pounds, harvested and homogenized in a lysis buffer [1% Triton X-100, 320 nM sucrose, 5 mM EDTA, 10 mM 
Tris–HCl and 2 mM DTT (1,4-dithio-DL-threitol) buffer (pH 7.6)]. Protein aliquots (100 μ g) were stained at 
37 °C for 60 min with fluorescent caspase-3 substrate N-acetyl-Asp-Glu-Val-Asp-AMC (AMC = 7-amino
-4-methylcoumarin) (Sigma Co.). Substrate hydrolysis was measured after 60 min by monitoring the release of 
AMC using a spectrofluorimeter (excitation at 370 nm, emission at 460 nm).
Statistical analysis. All of the values are the means ± SD (standard deviation) of not less than three meas-
urements starting from three different cell cultures. Multiple comparisons were made by ANOVA followed by the 
Tukey–Kramer multiple comparison test (* * P < 0.01, * P < 0.05), using GraphPad Software.
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